The estimated Net Worth of Lisa La Vange is at least 466 千$ dollars as of 3 September 2024. Lisa Vange owns over 650 units of Simulations Plus stock worth over 223,370$ and over the last 5 years he sold SLP stock worth over 160,027$. In addition, he makes 82,263$ as Independent Director at Simulations Plus.
Lisa has made over 5 trades of the Simulations Plus stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 650 units of SLP stock worth 23,368$ on 3 September 2024.
The largest trade he's ever made was selling 992 units of Simulations Plus stock on 27 July 2023 worth over 48,896$. On average, Lisa trades about 119 units every 14 days since 2019. As of 3 September 2024 he still owns at least 6,808 units of Simulations Plus stock.
You can see the complete history of Lisa Vange stock trades at the bottom of the page.
Dr. Lisa LaVange Ph.D. serves as Independent Director of the Company. Dr. LaVange currently serves as Professor and Associate Chair of the Department of Biostatistics in the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill. At UNC, she directs the establishment of a new Master's in Public Health (MPH) program with a concentration in data science, and is planning a regulatory science curriculum focused on statistical methodologies in two areas: precision medicine and real-world evidence. In addition, she is currently Principal Investigator (PI) of the coordinating centers for two large and complex trial networks: the NICHD-sponsored Adolescent Medicine Trials in HIV/AIDS Interventions Network (ATN) and the NHLBI-sponsored Precision Medicine in Severe and Exacerbation-Prone Asthma Network (PreciSE). From 2011 to 2017, Dr. LaVange served as Director of the Office of Biostatistics in the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). In this role, she directed 215 statistical reviewers, analysts, and support staff involved in the development and application of statistical methodology for drug regulation. She was responsible for statistical review of all investigational drugs, therapeutic biologics, biosimilar products, and generic drugs. She also chaired the Statistical Policy Council and was a member of CDER's Medical Policy Council, setting statistical policy and overseeing statistical guidance development and publication for the Center. Previously, she worked for six years at Quintiles, Inc. (now IQVIA), serving as Vice President of Biostatistics for her last three years. Quintiles is the largest pharmaceutical outsourcing services company in the U.S. In this role, she directed over 200 statisticians and programmers located in five offices across North America, supporting clinical trial operations, regulatory submissions, and post-marketing evaluations for a variety of large and small pharmaceutical and biotechnology compani
As the Independent Director of Simulations Plus, the total compensation of Lisa LaVange at Simulations Plus is 82,263$. There are 15 executives at Simulations Plus getting paid more, with Shawn M. O'Connor having the highest compensation of 544,231$.
Lisa LaVange is 66, he's been the Independent Director of Simulations Plus since 2019. There are 4 older and 10 younger executives at Simulations Plus. The oldest executive at Simulations Plus Inc. is Walter S. Woltosz M.A.S., M.S., 76, who is the Co-Founder & Chairman.
Lisa's mailing address filed with the SEC is 42505 10TH STREET, WEST, , LANCASTER, CA, 93534.
Over the last 21 years, insiders at Simulations Plus have traded over 70,055,940$ worth of Simulations Plus stock and bought 24,000 units worth 1,395,840$ . The most active insiders traders include Walter Swoltosz Virginia E ...、Walter S Woltosz、Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of 571,025$. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth 21,848$.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
Simulations Plus executives and other stock owners filed with the SEC include: